Healthcare Finance News January 25, 2026
Ferrin Williams, PharmD MBA, chief pharmacy officer at Scripta Insights, gives insights in this Q&A.
In December, Novo Nordisk announced that the Food and Drug Administration had approved its once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the United States. It remains the only GLP-1 pill on the market, though Eli Lilly will potentially get FDA approval in the second quarter and other drugmakers are not far behind.
Ferrin Williams, PharmD MBA, chief pharmacy officer at Scripta Insights, was asked what happens now, the benefits of a pill over an injectable and how these medications affect care plans for patients.
Q. Now that the Wegovy pill is here, people want to know, how do I get this...
Today's Sponsors
Today's Sponsor